title: Parenteral ferumoxytol interaction with magnetic resonance imaging: a case report, review of the literature and advisory warning.
abstract: BACKGROUND
  Ferumoxytol is a safe and effective parenteral therapy used for the treatment of iron deficiency anaemia that has recently been approved for use in North America and in Europe.
  
  
  METHODS
  Ferumoxytol consists of a superparamagnetic iron oxide (SPIO) core, which causes T1, T2 and T2* shortening effects, and a carbohydrate shell, which results in a prolonged intravascular half life.
  
  
  RESULTS
  These properties are under-reported and not well recognised. They can interfere with MRI interpretation, potentially masking enhancement and rendering examinations non-diagnostic or simulating pathologic disease states. Both radiologists and non-radiologist physicians must consider the potential interaction of ferumoxytol with MRI when interpreting and prescribing MRI examinations in their patients.
  
  
  CONCLUSIONS
  • Ferumoxytol has recently been approved for the treatment of iron deficiency anaemia. • Ferumoxytol is a small iron oxide particle with prolonged intravascular half life and T1, T2 and T2* shortening effects. • Administration of ferumoxytol can mask enhancement, rendering MRI studies potentially non-diagnostic. • Ferumoxytol can mimic diseases such as haemosiderosis, haemochromatosis and superficial siderosis. • Ferumoxytol interactions with MRI must be recognised by radiologists and non-radiologist physicians.
authors.affiliation: The Ottawa Hospital, The University of Ottawa, 1053 Carling Avenue, Ottawa, Ontario, Canada, K1Y 4E9, nschieda@toh.on.ca.
authors.forename: Nicola
authors.initials: N
authors.lastname: Schieda